The company reported Q3 profit of $1.49 per share versus $1.45 consensus. Its revenues reduced by 7.4% y/y to $17.102 bln, missing consensus of $17.474 bln.
Johnson & Johnson revised upwards its EPS FY15 guidance to $6.15-6.20 from $6.10-6.20. The analysts' consensus forecast for the company's EPS FY15 stands at $6.18.
JNJ rose to $96.25 ( 0.27%) in pre-market trading.